131 related articles for article (PubMed ID: 18234299)
1. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1.
Hoekstra AV; Ward EC; Hardt JL; Lurain JR; Singh DK; Buttin BM; Schink JC; Kim JJ
Gynecol Oncol; 2008 Mar; 108(3):609-18. PubMed ID: 18234299
[TBL] [Abstract][Full Text] [Related]
2. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma.
Ward EC; Hoekstra AV; Blok LJ; Hanifi-Moghaddam P; Lurain JR; Singh DK; Buttin BM; Schink JC; Kim JJ
Endocrinology; 2008 Apr; 149(4):1942-50. PubMed ID: 18096667
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1.
Berry E; Hardt JL; Clardy J; Lurain JR; Kim JJ
Gynecol Oncol; 2009 Feb; 112(2):331-6. PubMed ID: 19041124
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells.
Jin X; Gossett DR; Wang S; Yang D; Cao Y; Chen J; Guo R; Reynolds RK; Lin J
Br J Cancer; 2004 Nov; 91(10):1808-12. PubMed ID: 15505622
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis.
Neubauer NL; Ward EC; Patel P; Lu Z; Lee I; Blok LJ; Hanifi-Moghaddam P; Schink J; Kim JJ
Horm Cancer; 2011 Jun; 2(3):170-81. PubMed ID: 21760855
[TBL] [Abstract][Full Text] [Related]
6. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
7. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells.
Goto T; Takano M; Albergaria A; Briese J; Pomeranz KM; Cloke B; Fusi L; Feroze-Zaidi F; Maywald N; Sajin M; Dina RE; Ishihara O; Takeda S; Lam EW; Bamberger AM; Ghaem-Maghami S; Brosens JJ
Oncogene; 2008 Jan; 27(1):9-19. PubMed ID: 17599040
[TBL] [Abstract][Full Text] [Related]
8. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of PROM2 Enhances Paclitaxel Sensitivity in Endometrial Cancer Cells by Regulating the AKT/FOXO1 Pathway.
Jiang J; Zhang C; Wang J; Zhu Y; Wang X; Mao P
Anticancer Agents Med Chem; 2023; 23(19):2127-2134. PubMed ID: 37670696
[TBL] [Abstract][Full Text] [Related]
10. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
Zhuo Z; Yu H
Oncotarget; 2017 Apr; 8(17):28042-28051. PubMed ID: 28427207
[TBL] [Abstract][Full Text] [Related]
11. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
Zhao Z; Li C; Xi H; Gao Y; Xu D
Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
[TBL] [Abstract][Full Text] [Related]
12. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
15. FOXO1-dependent DNA damage repair is regulated by JNK in lung cancer cells.
Ju Y; Xu T; Zhang H; Yu A
Int J Oncol; 2014 Apr; 44(4):1284-92. PubMed ID: 24452601
[TBL] [Abstract][Full Text] [Related]
16. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
[TBL] [Abstract][Full Text] [Related]
17. Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
Zou J; Hong L; Luo C; Li Z; Zhu Y; Huang T; Zhang Y; Yuan H; Hu Y; Wen T; Zhuang W; Cai B; Zhang X; Huang J; Cheng J
Cancer Sci; 2016 Dec; 107(12):1806-1817. PubMed ID: 27636742
[TBL] [Abstract][Full Text] [Related]
18. Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer.
Wang Y; Hanifi-Moghaddam P; Hanekamp EE; Kloosterboer HJ; Franken P; Veldscholte J; van Doorn HC; Ewing PC; Kim JJ; Grootegoed JA; Burger CW; Fodde R; Blok LJ
Clin Cancer Res; 2009 Sep; 15(18):5784-93. PubMed ID: 19737954
[TBL] [Abstract][Full Text] [Related]
19. Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells.
Ding J; Li M; Deng L; Li T
Biomed Res Int; 2018; 2018():8372085. PubMed ID: 30175145
[TBL] [Abstract][Full Text] [Related]
20. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
